AR091633A1 - Solucion inyectable de acetaminofen para su administracion por via espinal - Google Patents
Solucion inyectable de acetaminofen para su administracion por via espinalInfo
- Publication number
- AR091633A1 AR091633A1 ARP130102331A AR091633A1 AR 091633 A1 AR091633 A1 AR 091633A1 AR P130102331 A ARP130102331 A AR P130102331A AR 091633 A1 AR091633 A1 AR 091633A1
- Authority
- AR
- Argentina
- Prior art keywords
- injectable
- solution
- acetaminofen
- espinal
- administration via
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title abstract 7
- 229960005489 paracetamol Drugs 0.000 title abstract 4
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 229940102223 injectable solution Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940127245 spinal anesthetics Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001154A ITMI20121154A1 (it) | 2012-06-29 | 2012-06-29 | Soluzione iniettabile di acetaminofene per la somministrazione spinale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091633A1 true AR091633A1 (es) | 2015-02-18 |
Family
ID=46690603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102331 AR091633A1 (es) | 2012-06-29 | 2013-06-28 | Solucion inyectable de acetaminofen para su administracion por via espinal |
Country Status (44)
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0162115B1 (ko) * | 1993-04-14 | 1998-11-16 | 노자키 지로 | 용존산소 감소장치 |
| US6171298B1 (en) * | 1996-05-03 | 2001-01-09 | Situs Corporation | Intravesical infuser |
| FR2751875B1 (fr) | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
| FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
| DE10112325A1 (de) * | 2001-03-13 | 2002-10-02 | Fresenius Kabi De Gmbh | Lagerstabile Fertiginfusionslösungen des Paracetamols |
| WO2003051398A1 (en) * | 2001-12-18 | 2003-06-26 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Parenteral composition of paracetamol |
| FR2851164B1 (fr) | 2003-02-14 | 2005-04-22 | Xuan Tho Nguyen | Formulation liquide injectable de paracetamol |
| DE102005037653A1 (de) * | 2005-08-05 | 2007-02-15 | Theraselect Gmbh | Stabile, flüssige Formulierung von Paracetamol |
| AU2006346318B2 (en) * | 2006-07-18 | 2011-02-10 | Genfarma Laboratorio S.L. | Injectable liquid paracetamol formulation |
| CN101015542A (zh) * | 2007-02-13 | 2007-08-15 | 天津生机集团有限公司 | 家畜用复方对乙酰氨基酚注射液及其制备方法 |
| MD3528G2 (ro) * | 2007-09-28 | 2008-11-30 | Сергей ШАНДРУ | Metodă de anestezie spinală continuă la pacienţii în etate |
| CA2705733C (en) * | 2007-11-13 | 2015-02-03 | Cadence Pharmaceuticals | Reduced dose intravenous acetaminophen |
| WO2009098716A2 (en) | 2008-01-17 | 2009-08-13 | Aptuit Laurus Private Limited | Stable pharmaceutical aqueous compositions |
| WO2009143558A1 (en) * | 2008-05-26 | 2009-12-03 | Silphion Pty Limited | Injectable formulations |
| EP2243477A1 (de) | 2009-04-22 | 2010-10-27 | Fresenius Kabi Deutschland GmbH | Paracetamol zur parenteralen Verabreichung |
| JP2013006770A (ja) * | 2009-10-09 | 2013-01-10 | Ssp Co Ltd | アセトアミノフェン含有経口液剤 |
| PH12012502444A1 (en) * | 2010-06-30 | 2013-02-11 | Troikaa Pharmaceuticals Ltd | Pharmaceutical compositions comprising paracetamol and process for preparing the same |
-
2012
- 2012-06-29 IT IT001154A patent/ITMI20121154A1/it unknown
-
2013
- 2013-06-27 KR KR1020147036909A patent/KR102118227B1/ko not_active Expired - Fee Related
- 2013-06-27 WO PCT/IB2013/055277 patent/WO2014002042A1/en not_active Ceased
- 2013-06-27 MA MA37811A patent/MA37811B1/fr unknown
- 2013-06-27 EA EA201500065A patent/EA028909B1/ru unknown
- 2013-06-27 AP AP2014008152A patent/AP2014008152A0/xx unknown
- 2013-06-27 JP JP2015519450A patent/JP5876620B2/ja not_active Expired - Fee Related
- 2013-06-27 MY MYPI2014703994A patent/MY169251A/en unknown
- 2013-06-27 MX MX2014015402A patent/MX369264B/es active IP Right Grant
- 2013-06-27 GE GEAP201313679A patent/GEP201706689B/en unknown
- 2013-06-27 NZ NZ703829A patent/NZ703829A/en not_active IP Right Cessation
- 2013-06-27 MD MDA20140138A patent/MD4537C1/ro not_active IP Right Cessation
- 2013-06-27 PE PE2014002536A patent/PE20150331A1/es active IP Right Grant
- 2013-06-27 HR HRP20160706TT patent/HRP20160706T1/hr unknown
- 2013-06-27 ES ES13765450.5T patent/ES2578012T3/es active Active
- 2013-06-27 UA UAA201413899A patent/UA117101C2/uk unknown
- 2013-06-27 SG SG11201408479WA patent/SG11201408479WA/en unknown
- 2013-06-27 PL PL13765450.5T patent/PL2874602T3/pl unknown
- 2013-06-27 RS RS20160435A patent/RS54844B1/sr unknown
- 2013-06-27 HU HUE13765450A patent/HUE029431T2/en unknown
- 2013-06-27 DK DK13765450.5T patent/DK2874602T3/en active
- 2013-06-27 CN CN201380034500.0A patent/CN104487051B/zh not_active Expired - Fee Related
- 2013-06-27 PT PT137654505T patent/PT2874602T/pt unknown
- 2013-06-27 EP EP13765450.5A patent/EP2874602B1/en active Active
- 2013-06-27 CA CA2876801A patent/CA2876801C/en active Active
- 2013-06-27 SI SI201330208A patent/SI2874602T1/sl unknown
- 2013-06-27 ME MEP-2016-118A patent/ME02431B/me unknown
- 2013-06-27 AU AU2013282753A patent/AU2013282753B2/en not_active Ceased
- 2013-06-27 US US14/411,532 patent/US11344517B2/en active Active
- 2013-06-27 SG SG10201704482YA patent/SG10201704482YA/en unknown
- 2013-06-27 BR BR112014032818-8A patent/BR112014032818B1/pt not_active IP Right Cessation
- 2013-06-28 AR ARP130102331 patent/AR091633A1/es unknown
-
2014
- 2014-12-18 TN TN2014000526A patent/TN2014000526A1/fr unknown
- 2014-12-18 NI NI201400147A patent/NI201400147A/es unknown
- 2014-12-22 ZA ZA2014/09478A patent/ZA201409478B/en unknown
- 2014-12-23 IL IL236423A patent/IL236423A/en active IP Right Grant
- 2014-12-26 CL CL2014003536A patent/CL2014003536A1/es unknown
- 2014-12-26 CU CUP2014000150A patent/CU20140150A7/es unknown
- 2014-12-29 DO DO2014000302A patent/DOP2014000302A/es unknown
-
2015
- 2015-01-08 EC ECIEPI2015500A patent/ECSP15000500A/es unknown
- 2015-01-27 CR CR20150036A patent/CR20150036A/es unknown
- 2015-01-27 PH PH12015500178A patent/PH12015500178B1/en unknown
- 2015-01-27 CO CO15015754A patent/CO7240357A2/es unknown
-
2016
- 2016-01-19 US US15/001,064 patent/US20160128955A1/en not_active Abandoned
- 2016-06-28 CY CY20161100584T patent/CY1117691T1/el unknown
- 2016-07-26 SM SM201600248T patent/SMT201600248B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| MX2015009772A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| MX2015000990A (es) | Analogos del glucagon. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CL2016000950A1 (es) | Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2. | |
| CL2013001250A1 (es) | Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion. | |
| MX2015012783A (es) | Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13). | |
| CL2015003634A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| CO7461127A2 (es) | Código para la configuración de un dispositivo de atención al paciente | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
| ECSP10010567A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
| CL2010001594A1 (es) | Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida. | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2011000387A1 (es) | Combinacion que comprende a) 6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol y b) paracetamol; forma de dosificacion; uso para tratar osteoartritis y dolor. | |
| BR112015015938A2 (pt) | uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto | |
| AR091633A1 (es) | Solucion inyectable de acetaminofen para su administracion por via espinal | |
| MX372644B (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
| CL2013000835A1 (es) | Compuestos derivados de metilciclohexano, moduladores del oxido nitrico; composicion farmaceutica que los comprende y su uso en el tratamiento y/o profilaxis del dolor cronico o agudo. | |
| UY32985A (es) | Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona | |
| PE20160748A1 (es) | Formacion de costra artificial porosa semipermeable | |
| AR099638A1 (es) | El uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmacéuticamente aceptable del mismo en la prevención y el tratamiento de la diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |